Dark Pharma · DP-033
WE VOTED AT 11:47 A.M. THE FDA APPROVAL WAS FORTY-ONE YEARS OLD. I INITIALLED THE EXECUTIVE SUMMARY.
In August 2015, Helion Pharmaceuticals voted to raise the price of Parasitrol from $13.50 to $750 per tablet, a decision that prioritized profit over patient access. At the center of the board’s approval was CEO Marcus Veld, who presented a pricing strategy that received minimal scrutiny.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
B-School Noir
BN-026
HE APPROVED THE PORTFOLIO. THE ENDOWMENT FUNDED A CATHOLIC ETHICS CHAI...
Shared: Ethical Decision-Making Model, Stakeholder Theory, Risk Management Framework
The Raid
HJ-031
HE POSTED THE SEVERANCE LIST AT 6 A.M. THE UNION HAD AGREED TO THE CUT...
Shared: Stakeholder Theory, Ethical Decision-Making Model
Collapse Files
CF-043
I FILED THE COLUMN REPORT ON APRIL 11TH. THEY SCHEDULED A BOARD REVIEW...
Shared: Risk Management Framework, Stakeholder Theory
Machine Room
MX-038
HE CHOSE THE DESERT IN 2015. THE GROUND WAS ALREADY SOLD TO SOMEONE EL...
Shared: Risk Management Framework